Coagulopathy with Chimerism; the Risks of Rituximab

Rituximab is a chimeric monoclonal anti-CD20 antibody. It is a well-tolerated medication used in a variety of hematologic and autoimmune conditions. The most common side effects are infusion reactions and cytopenias, including thrombocytopenia. Coagulation abnormalities and fibrinolysis are quite rare and are reported only twice in the literature.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research